Travere Therapeutics Inc Market Cap ($4.75 Billion)
Market Cap & Net Worth: Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc market cap. Travere Therapeutics Inc (NASDAQ:TVTX) has a market capitalization of $4.75 Billion ($4.75 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3569 globally and #1284 in its home market, demonstrating a -3.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Travere Therapeutics Inc's stock price $50.39 by its total outstanding shares 94261082 (94.26 Million). Also see Travere Therapeutics Inc (TVTX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Travere Therapeutics Inc Market Cap History (2015–2026)
Travere Therapeutics Inc market cap history from 2015 to 2026. Data shows growth from $1.82 Billion to $4.75 Billion (9.17% CAGR). Check Travere Therapeutics Inc (TVTX) share price today for real-time trading data and today's change.
Index Memberships
Travere Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.18% | #94 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #415 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.26% | #62 of 263 |
Weight: Travere Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Travere Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Travere Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Travere Therapeutics Inc (TVTX) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.34x
Travere Therapeutics Inc's market cap is 7.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.78 Billion | $133.59 Million | -$47.90 Million | 13.36x | N/A |
| 2017 | $1.99 Billion | $154.94 Million | -$59.73 Million | 12.82x | N/A |
| 2018 | $2.13 Billion | $164.25 Million | -$102.68 Million | 12.99x | N/A |
| 2019 | $1.34 Billion | $175.34 Million | -$146.43 Million | 7.63x | N/A |
| 2020 | $2.57 Billion | $198.32 Million | -$169.43 Million | 12.95x | N/A |
| 2021 | $2.93 Billion | $131.84 Million | -$180.09 Million | 22.19x | N/A |
| 2022 | $1.98 Billion | $109.46 Million | -$278.48 Million | 18.11x | N/A |
| 2023 | $847.41 Million | $145.24 Million | -$111.40 Million | 5.83x | N/A |
| 2024 | $1.64 Billion | $233.18 Million | -$321.55 Million | 7.04x | N/A |
| 2025 | $3.60 Billion | $490.73 Million | -$25.55 Million | 7.34x | N/A |
Competitor Companies of TVTX by Market Capitalization
Companies near Travere Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see Travere Therapeutics Inc assets under control for a full breakdown of the balance sheet.
Key companies related to Travere Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Travere Therapeutics Inc (2015–2026)
Market capitalization of Travere Therapeutics Inc from 2015 to today. Between 2015 and today, Travere Therapeutics Inc's market cap moved from $1.82 Billion to $ 4.75 Billion, with a yearly change of 9.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.75 Billion | +31.88% |
| 2025 | $3.60 Billion | +119.35% |
| 2024 | $1.64 Billion | +93.77% |
| 2023 | $847.41 Million | -57.25% |
| 2022 | $1.98 Billion | -32.25% |
| 2021 | $2.93 Billion | +13.89% |
| 2020 | $2.57 Billion | +91.94% |
| 2019 | $1.34 Billion | -37.25% |
| 2018 | $2.13 Billion | +7.40% |
| 2017 | $1.99 Billion | +11.30% |
| 2016 | $1.78 Billion | -1.87% |
| 2015 | $1.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 1st, 2026 the market cap of Travere Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.75 Billion USD |
| MoneyControl | $4.75 Billion USD |
| MarketWatch | $4.75 Billion USD |
| marketcap.company | $4.75 Billion USD |
| Reuters | $4.75 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola a… Read more